Results 91 to 100 of about 18,425 (234)

Treprostinil: Mechanism of Action, Clinical, and Translational Science

open access: yesClinical and Translational Science, Volume 19, Issue 11, November 2026.
ABSTRACT Treprostinil is a synthetic prostacyclin analogue with a tricyclic benzindene structure that confers markedly enhanced metabolic stability relative to native prostacyclin, enabling delivery by four distinct routes—intravenous, subcutaneous, inhaled, and oral—that together constitute a mainstay of pharmacotherapy for pulmonary arterial ...
Muhammad Sameed   +2 more
wiley   +1 more source

Use of Geometric Mean in Bioequivalence Trials [PDF]

open access: yes, 2015
Bioequivalence data often do not follow the normality assumption on the linear (original) scale, therefore in that situation, the use of the logarithmic transformation is recommended.
Siddiqui, Afaq Ahmed, Rasheed, Abdur
core  

A note on an individual bioequivalence setting [PDF]

open access: yes, 2005
We give a new simpler proof along with a generalization for the inequality of Yao and Iyer \cite{yao} arising in bioequivalence studies and by using a nonparametric approach we also discuss an extension of the individual bioequivalence setting to the ...
Surulescu, N., Surulescu, Christina
core   +1 more source

Implementation of a reference-scaled average bioequivalence approach for highly variable generic drug products of agomelatine in Chinese subjects

open access: yesActa Pharmaceutica Sinica B, 2016
The aim of this study was to apply the reference-scaled average bioequivalence (RSABE) approach to evaluate the bioequivalence of 2 formulations of agomelatine, and to investigate the pharmacokinetic properties of agomelatine in Chinese healthy male ...
Fang Tang   +10 more
doaj   +1 more source

Phase 1 Evaluation of the Pharmacokinetics of Sevasemten (EDG‐5506) for Potential Food Effect and Drug–Drug Interaction With a CYP3A4 Moderate Inhibitor

open access: yesClinical and Translational Science, Volume 19, Issue 11, November 2026.
ABSTRACT Sevasemten (EDG‐5506) is an investigational, small molecule, in development for the treatment of Becker and Duchenne muscular dystrophy. In vitro data suggest sevasemten is a substrate for cytochrome P450 (CYP)3A4. Here, we investigate whether the pharmacokinetics (PK) of sevasemten are affected when co‐administered with a moderate CYP3A4 ...
Molly Madden   +2 more
wiley   +1 more source

In vivo and in vitro bioequivalence testing

open access: yes, 2014
10.4172/jbb.1000182Journal of Bioequivalence and Bioavailability6267 ...
Lu, Y, Zhu, S, Chow, S.-C
core   +1 more source

Bioequivalence studies for levothyroxine [PDF]

open access: yesThe AAPS Journal, 2005
The Food and Drug Administration (FDA) Guidance for Bioavailability and Bioequivalence Studies for Levothyroxine has been challenged by companies that manufacture brand-name products. Their contention is that the current guidance does not adequately address the endogenous background levels of the drug, and that the ratios of the PK parameters, a basis ...
openaire   +2 more sources

A single-dose, randomized, open-label, four-period, crossover equivalence trial comparing the clinical similarity of the proposed biosimilar rupatadine fumarate to reference Wystamm® in healthy Chinese subjects

open access: yesFrontiers in Pharmacology
PurposeThe aim of this study was to evaluate the bioequivalence of two formulations of rupatadine (10-mg tablets) under fasting and fed conditions in healthy Chinese subjects.MethodsA total of 72 subjects were randomly assigned to the fasting cohort (n =
Sisi Lin   +10 more
doaj   +1 more source

A Proposal of Conducting Bioequivalence Trials with Gastric pH Modulators for Two Oral Formulations Demonstrating Different Dissolution Profiles at Elevated pH

open access: yesClinical and Translational Science, 2019
In this paper, a special case for bioequivalence evaluation of oral formulations is discussed. Drug formulations with different forms of active moieties (e.g., free base and salt) may yield different dissolution characteristics and, thus, differ in ...
Hao Zhu   +7 more
doaj   +1 more source

First‐In‐Human Study of Mirogabalin (BM2216) Sustained‐Release Tablets: Safety, Tolerability, Pharmacokinetics, Food Effect and Dose Proportionality With Comparison to Mirogabalin Besylate in Healthy Participants

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10795-10813, November 2026.
ABSTRACT Aim To characterise the pharmacokinetics (PKs) and safety of BM2216 sustained‐release (SR) tablets after single‐dose oral administration under fasted/fed conditions in healthy participants, assess the effect of food and dose proportionality, and compare the single and multiple‐dose PK of BM2216 SR tablets with mirogabalin besylate tablets to ...
Peiyang Song   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy